| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Daré Bioscience Inc (NASDAQ: DARE)
DARE Technical Analysis
5
| As on 9th Jun 2023 DARE STOCK Price closed @ 0.98 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.29 & Strong Sell for SHORT-TERM with Stoploss of 1.66 we also expect STOCK to react on Following IMPORTANT LEVELS. |
DARESTOCK Price
| Open | 0.99 | Change | Price | % |
| High | 1.00 | 1 Day | 0.00 | 0.00 |
| Low | 0.98 | 1 Week | -0.03 | -2.97 |
| Close | 0.98 | 1 Month | -0.01 | -1.01 |
| Volume | 294100 | 1 Year | -1.02 | -51.00 |
| 52 Week High 2.10 | 52 Week Low 0.82 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| DARE Daily Charts |
DARE Intraday Charts |
Whats New @ Bazaartrend |
DARE Free Analysis |
|
|
DARE Important Levels Intraday
| RESISTANCE | 1.02 |
| RESISTANCE | 1.01 |
| RESISTANCE | 1.00 |
| RESISTANCE | 0.99 |
| SUPPORT | 0.97 |
| SUPPORT | 0.96 |
| SUPPORT | 0.95 |
| SUPPORT | 0.94 |
DARE Forecast April 2024
| 4th UP Forecast | 2.04 |
| 3rd UP Forecast | 1.7 |
| 2nd UP Forecast | 1.49 |
| 1st UP Forecast | 1.28 |
| 1st DOWN Forecast | 0.68 |
| 2nd DOWN Forecast | 0.47 |
| 3rd DOWN Forecast | 0.26 |
| 4th DOWN Forecast | -0.08 |
DARE Weekly Forecast
| 4th UP Forecast | 1.37 |
| 3rd UP Forecast | 1.24 |
| 2nd UP Forecast | 1.17 |
| 1st UP Forecast | 1.09 |
| 1st DOWN Forecast | 0.87 |
| 2nd DOWN Forecast | 0.79 |
| 3rd DOWN Forecast | 0.72 |
| 4th DOWN Forecast | 0.59 |
DARE Forecast2024
| 4th UP Forecast | 3.52 |
| 3rd UP Forecast | 2.71 |
| 2nd UP Forecast | 2.2 |
| 1st UP Forecast | 1.7 |
| 1st DOWN Forecast | 0.26 |
| 2nd DOWN Forecast | -0.24 |
| 3rd DOWN Forecast | -0.75 |
| 4th DOWN Forecast | -1.56 |
Daré Bioscience Inc ( NASDAQ USA Symbol : DARE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
DARE Business Profile
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California. Address: 3655 Nobel Drive, San Diego, CA, United States, 92122
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service